Altern Ther Health Med. 2023 Oct 27:AT8958. Online ahead of print.
ABSTRACT
OBJECTIVE: To evaluate the effect of metformin on the survival of patients with diabetes mellitus complicated with renal cell carcinoma by Meta-analysis.
METHODS: To collect the required data, we looked through the databases of the Cochrane Library, PubMed, and EMBASE, as well as the network for querying registration data from clinical trials (https://clinicaltrials.gov). Retrieve relevant ongoing or closed clinical trials. To avoid publication bias, the search process is limited to randomized controlled trials, and the search results are not limited to language, publication time, or other restrictions. All included studies need to be evaluated according to the quality evaluation standard of the Cochran system evaluation manual. The relevant data were statistically analyzed by Revman 5.3 software. In the evaluation of overall survival (OS) and progression-free survival (PFS), the index of hazard risk (HR) was selected in this paper.
RESULTS: Eight cohort studies were included in the analysis. Partial and metastatic subgroup analysis of renal cell carcinoma demonstrated no significant effect of metformin on PFS, CSS, or OS. There was no evidence of publication bias, according to the findings.
CONCLUSION: This systematic review and meta-analysis found that metformin did not improve survival rates for diabetic patients with renal cell carcinoma.
PMID:37883777
